Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

The Lancet
May 15, 2021 Volume 397 Number 10287 p1781-1858, e12-e14
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
Mehreen S Datoo, et al.
Background
Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in African children. We therefore assessed a new candidate vaccine for safety and efficacy.
Interpretation
R21/MM appears safe and very immunogenic in African children, and shows promising high-level efficacy.